WO1994010983A1 - Peroral pharmaceutical preparation releasable in lower digestive tract - Google Patents
Peroral pharmaceutical preparation releasable in lower digestive tract Download PDFInfo
- Publication number
- WO1994010983A1 WO1994010983A1 PCT/JP1993/001608 JP9301608W WO9410983A1 WO 1994010983 A1 WO1994010983 A1 WO 1994010983A1 JP 9301608 W JP9301608 W JP 9301608W WO 9410983 A1 WO9410983 A1 WO 9410983A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- release
- gastrointestinal tract
- oral pharmaceutical
- pharmaceutical preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- the present invention relates to an oral pharmaceutical preparation having a lower gastrointestinal release property. Specifically, tablets are disintegrated and released only when they reach the large intestine without passing through the stomach without being affected by gastric juice during oral administration, without any change in the small intestine, and the active ingredient is absorbed in the large intestine It relates to an oral pharmaceutical preparation.
- the concentration of the pharmacologically active substance at the site of release is increased to a high level by selective release of the pharmacologically active substance in the large intestine, and a more effective local effect than conventional preparations can be expected.
- the pharmacologically active substances proteinaceous and peptide-based substances which lose their activity due to degradation in the small intestine, the activity of proteolytic enzymes when such drugs are selectively released in the large intestine. It is possible that these drugs are absorbed from the low intestine. Therefore, it is clear from the above advantages that oral pharmaceutical preparations are much more easily accepted than injections and suppositories.
- oral preparations that release the large intestine by combining a polymer that dissolves only at pH 5.5 or higher with an insoluble polymer (European Patent No. 405,900), dissolve at pH 7.0 or higher Solid oral dosage form coated with an appropriate amount of an anionic polymer (trade name: Eudragit S, manufactured by Laem Co., Ltd.) (International Publication WO83000435), dissolved at pH 7.0 or higher Anionic polymer (trade name: Eudragit S or L, manufactured by Laem) and poorly water-soluble methacrylic acid Oral formulation (European Patent No.
- Each of these formulations is a drug release system triggered by an increase in intestinal pH, and an appropriate amount of anionic polymer is coated so that the drug is not released within the intestinal residence time of the formulation. It is coated or blended with an insoluble polymer.
- WO 90/13286 discloses a nucleus composed of a main drug and an excipient, a first layer covering a nucleus composed of an enteric component, a second layer covering a first layer composed of a non-enteric component, And an oral formulation comprising a third layer covering a second layer of an enteric component.
- a cationic polymer is used in the second layer, It is very difficult to control colon-specific release because a third layer is provided to control the release of the substance.
- the second layer dissolves in the small intestine and is in the form of a drug that is likely to leak drug before reaching the large intestine.
- the present invention solves these problems of the prior art, and the tablet passes through the stomach without being affected by gastric juice, without any change in the small intestine, and is disintegrated and released only when the tablet reaches the large intestine.
- the purpose of the present invention is to provide an oral pharmaceutical preparation which is absorbed in the large intestine.
- the oral pharmaceutical preparation having a lower gastrointestinal tract release comprises a solid drug comprising a core containing an active ingredient and an inner layer comprising a cationic polymer and an outer layer comprising an anionic polymer, respectively. It has a coating structure.
- the present invention provides a novel drug comprising a solid drug comprising a core containing an active ingredient which is disintegrated and released in the lower gastrointestinal tract and containing a therapeutically active ingredient, and a coating layer comprising the following layers (1) to (4).
- Oral pharmaceutical preparation comprising a solid drug comprising a core containing an active ingredient which is disintegrated and released in the lower gastrointestinal tract and containing a therapeutically active ingredient, and a coating layer comprising the following layers (1) to (4).
- Oral pharmaceutical preparation comprising a solid drug comprising a core containing an active ingredient which is disintegrated and released in the lower gastrointestinal tract and containing a therapeutically active ingredient.
- Layer An inner layer made of a cationic copolymer containing a suitable plasticizer or an anti-binding agent and soluble or swelling at a pH of 6.0 or less.
- This core solid drug is prepared by combining the therapeutic active ingredient, alone or with excipients, binders, disintegrants and absorption enhancers.
- examples of the excipient include lactose, crystalline cellulose, sodium crystalline carboxymethylcellulose, wheat starch, magnesium stearate and the like.
- Binders include microcrystalline cellulose, pullulan, gum arabic, sodium alginate Examples include lium, polyvinylpyrrolidone, and macrogol.
- disintegrant commonly used inert pharmaceutical substances such as carboxymethylcellulose, calcium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylstarch, starch, and sodium alginate are used.
- sugar ester For the purpose of promoting the absorption of the active ingredient, sugar ester, sucrose fatty acid ester, glycyrrhizinate, glycyrrhetinic acid, dipotassium glycyrrhizinate, bile acid, glycerin fatty acid ester, and [(2- (decylthio) ethyl] azaciclopentane)
- absorption promoters such as 2-one, adipic acid, basic amino acids, polyethylene glycol and sodium caprate.
- the solid preparation may be produced by encapsulating in a gelatin capsule, granulating or tableting.
- the therapeutic active ingredient contained in the solid drug is not particularly limited as long as it is effective when released in the lower gastrointestinal tract, and any can be used. Examples include peptides, proteins, anti-inflammatory agents, anti-tumor agents, antibiotics, chemotherapeutic agents, drugs for ulcerative colitis, drugs for irritable colitis (choline blockers), and constipation drugs.
- somatostatin insulin, calcitonin, vasopressin, gastrin, EGF (epidermal growth factor), ⁇ -h ANP ( ⁇ -human atrial natriuretic peptide), enkephalin, endolphin, GM— CSF (granulocyte macrophage colony stimulating factor), G—CSF (granulocyte colony stimulating factor), human growth hormone, glucagon, t- ⁇ ⁇ (tissue plasminogen activator), TNF (tumor necrosis factor) , TCGF (T cell growth factor), ACTH (adrenocorticotropic hormone), interleukin, inferon ferron, EPO (erythropoietin), perokinase, neocarzinostatin, bradykinin, immunoglobulin and its digests, Various allergens and their digests, ketoprofen, ibuprofen, Rofuenakku, indomethacin down, ketorola
- the cationic polymer that dissolves or swells at pH 6.0 or less and is used as the inner layer is a common name of aminoalkyl methacrylate copolymer [methyl methacrylate, butyl methacrylate, dimethyl methacrylate].
- This polymer layer (inner layer) is used at 1 to 40% by weight of the weight of the solid drug so that the film thickness becomes 10 to 300 // m.
- the solid drug is used immediately. The release of the active substance is regulated.
- a suitable plasticizer that can obtain a smooth coating film is preferably used.
- the plasticizer include triacetin, citrate, polyethylene glycol, and the like.
- the binding inhibitor include talc, titanium oxide, calcium phosphate, and hydrophobic light gay anhydride.
- the outer layer is an anionic polymer that dissolves easily above pH 5.5.
- useful polymers include methacrylic acid copolymer L (copolymer of methacrylic acid and methyl methacrylate, trade name: Eu dragit L 100 (Eudragit L 100), manufactured by Reem Co.), which is a generic name, or meta-atalinoleic acid.
- Copolymer S (copolymer consisting of methacrylic acid and methyl methacrylate, trade name: Eud ragit S (Eudragit S), manufactured by Reem Co.), hydroxypropyl cellulose, hydroxyethyl cellulose phthalate, polyvinyl acetate phthalate, Cellulose acetate tetraphthalate and cellulose acetate tetrahydrophthalate are included.
- the polymer is used at 1 to 40% by weight of the solid drug.
- FIG. 1 is a graph showing an in vitro drug release test.
- FIG. 2 is a graph showing an in vivo drug concentration test in vivo.
- Figure 3 is a graph showing the in vitro release test for coating weight change.
- FIG. 4 is a graph showing a release test of ketoprofen with respect to a change in pH.
- Figure 5 shows a release test of FITC dextran against pH change.
- FIG. 6 is a graph showing a calcitonin release test with respect to a change in pH.
- FIG. 7 is a graph showing a blood calcium concentration measurement test using dogs.
- Figure 8 is a graph showing the in vitro release test for changes in coating weight.
- FIG. 9 is a graph showing the effect of an absorption enhancer in vivo.
- ketoprofyun A solid drug consisting of a core containing ketoprofyun was prepared according to the following formulation. Ketoprofen 24.0 parts by weight
- Ketoprofen, lactose and magnesium stearate were uniformly mixed, and tablets having a diameter of 7 mm and a weight of 21 Omg were produced using a tableting machine.
- the solid coating was provided with the following coating.
- Eudragit E (trade name) 7.0 parts by weight
- This inner layer was applied by continuously spraying the above solution at 50 ° C onto the solid medicine which had been heated to 50 ° C in advance.
- O The weight gain of the solid drug is 30 mg o
- Eudragit S (trade name) 7.0 parts by weight
- the weight gain of the solid drug was 2 Omg.
- ketoprofyun A solid drug consisting of a core containing ketoprofyun was prepared according to the following formulation. Ketoprofen 24.0 parts by weight
- Ketoprofen, lactose and magnesium stearate were uniformly mixed, and tablets having a diameter of 7 mm and a weight of 21 Omg were produced using a tableting machine. The following coating was applied to the solid drug.
- This inner layer was applied by continuously spraying the above solution at room temperature on the solid medicine which had been heated to 50 ° C. in advance.
- the weight gain of the solid was 3 Omg. After drying, the following solution was further applied to the solid medicine as an intermediate layer.
- Polyethylene glycol 400 0.5 parts by weight
- Hydroxypropylcellulose was suspended in 95% ethanol, and a polyethylene glycol 400 solution was added. This solution was sprayed onto the solid drug which had been preheated to 50 ° C. The weight gain of the solid was 1 Omg.
- the solution was sprayed in the same manner as described above.
- the weight gain of the solid was 1 Omg.
- a release test of ketoprofen from the tablets prepared in Example 1 and Comparative Example 1 was performed. After incubating in a pH 2.0 buffer for 2 hours, the cells were incubated in a pH 7.4 buffer for 6 hours, and further incubated in a cecal solution. The composition of the cecal solution was made by suspending the cecal contents in a pH 7.4 phosphate buffer containing 125 mg of glucose and 4.1 mg of benzyl virogen. Released ketoprofen was measured by liquid chromatography.
- Figure 1 shows the results of the release test. In the figure, ⁇ indicates the release pattern from the tablet of Example 1, and • indicates the release pattern from the tablet of Comparative Example 1.
- Example 1 The tablets of Example 1 were administered to experimental animals (beagle dog, male, body weight 10 kg) under anesthesia.
- Figure 2 shows the results.
- Hata indicates the tablet of Example 1.
- ketoprofen was not initially observed in plasma despite its very good absorption. However, ketoprofen was significantly observed in plasma after 14 hours.
- Example Nos. 1 to 5 Each tablet (Sample Nos. 1 to 5) was subjected to a ketoprofen release test. After incubating for 4 hours in pH 7.4 buffer, the solution was switched to cecal solution. The results of the release test are shown in FIG. In the figure, ⁇ indicates sample No. 1 in Table 1, ⁇ indicates sample No. 2 in Table 1, ⁇ indicates sample N 0. 3 in Table 1, ⁇ indicates sample No. ⁇ in Table 1, ⁇ indicates sample No. 5 in Table 1, respectively.
- Granules containing ketoprofen were produced according to the following recipe.
- Hydroxypropyl cellulose 5. After mixing ketoprofen, lactose, corn starch and crystalline cellulose uniformly, add hydroxypropyl cellulose dissolved in purified water and knead. The mixture was granulated by an extrusion granulator having a cylindrical hole diameter of lmm, dried, and sized. The following coating was applied to the granules to form an inner layer. The weight increase per 1 mg of the granules was 5 m.
- Eudragit E (trade name) 7.0 parts by weight
- the above solution was continuously sprayed at room temperature on the granules previously heated to 50 ° C by a fluid coating device.
- the granules were dried, and the following solution was further applied to form an outer layer.
- the weight increase per 10 Omg of the granules was 1 Omg.
- Eudragit L (trade name) 7.0 parts by weight
- FIG. 4 shows the results of the release test.
- ⁇ indicates the release pattern at pH 2.0
- ⁇ indicates the release pattern at pH 7.4.
- ⁇ indicates the release pattern when switched to the cecal solution after being left for 4 hours at pH 7.4.
- fluorescein isothiocynate dextran (hereinafter abbreviated as FITC dextran) was used in the following formulation.
- the coating of the inner layer and the outer layer was performed in the same manner as in Example 1.
- a solid drug consisting of a core containing calcitonin was produced according to the following formulation.
- Calcitonin, lactose, magnesium stearate and sucrose fatty acid ester were uniformly mixed, and tablets with a diameter of 2 mm and a weight of 7 mg were produced using a tableting machine.
- a coating layer was further formed with magnesium stearate (1 part by weight) and lactose (99 parts by weight).
- the tablet was coated with the same inner and outer layers as in Example 1.
- FIG. 6 shows the results.
- ⁇ indicates the release pattern at pH 2.0
- ⁇ indicates the release pattern at pH 7.4.
- ⁇ indicates the release pattern when the solution was switched to the cecal solution after being left at pH 7.4 for 4 hours.
- Example 5 The tablets prepared in Example 5 were administered to dogs in the same manner as in Example 1, and the blood calcium concentration was measured.
- Fig. 7 shows the results.
- ⁇ shows the results of the tablet of Example 5
- ⁇ shows the results of the tablet of Example 5 without coating.
- FIG. 8 shows the results of the release test.
- ⁇ is the sample No. 1 in Table 2
- ⁇ is the sample No. 2 in Table 2
- ⁇ is the sample N 0. 3 in Table 2
- ⁇ is the sample in Table 2.
- No. 4 and ⁇ indicate sample No. ⁇ in Table 2, respectively.
- a fixative consisting of nuclei containing luciniton was prepared according to the following formulation.
- Eudragit E (trade name) 7.0 parts by weight
- This inner layer was applied by continuously spraying the above solution at 50 ° C onto the solid medicine which had been heated to 50 ° C in advance.
- the weight gain of the solid drug was 14 mg. After drying, the following solution was further applied. Oiled S 7.0 parts by weight
- the outer layer was applied by continuously spraying the above solution at 50 ° C. onto the solid medicine previously heated to 50 ° C.
- the weight gain of the solid drug was 14 m.
- Example 7 The tablets prepared in Example 7 were administered to dogs in the same manner as in Example 5, and the blood calcium concentration was measured.
- Fig. 9 shows the results.
- ⁇ indicates the sample No. 1 in Table 3
- ⁇ indicates the sample No. 2 in Table 3
- 2 indicates the sample No. 3 in Table 3
- ⁇ indicates the sample No. 3 in Table 3.
- 4 and ⁇ indicate the sample No. 5 in Table 3, respectively.
- the oral pharmaceutical preparation having a lower gastrointestinal tract release according to the present invention has a specific release of the active ingredient corresponding to a change in pH peculiar to the gastrointestinal tract. It is possible to significantly reduce the reduction or loss of utilization and the variation between solids as observed.
- the present invention has excellent properties such as being disintegrated and released only after reaching the lower intestinal tract, the large intestine, without being affected by the stomach or the small intestine, where the active ingredient is sufficiently absorbed and the therapeutic activity is significantly enhanced. It is useful as a pharmaceutical preparation by oral administration for the purpose of treating patients such as the colon or large intestine.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/432,202 US5654004A (en) | 1992-11-06 | 1993-11-05 | Oral pharmaceutical preparation releasable in the lower digestive tract |
AU53768/94A AU5376894A (en) | 1992-11-06 | 1993-11-05 | Peroral pharmaceutical preparation releasable in lower digestive tract |
KR1019950701773A KR0157280B1 (ko) | 1992-11-06 | 1993-11-05 | 하부소화관 방출성의 경구의약제제 |
EP93924185A EP0667148B1 (en) | 1992-11-06 | 1993-11-05 | Peroral pharmaceutical preparation releasable in lower digestive tract |
DK93924185T DK0667148T3 (da) | 1992-11-06 | 1993-11-05 | Peroralt farmaceutisk præparat, der udløses i den nedre del af mavetarmkanalen |
CA002148465A CA2148465C (en) | 1992-11-06 | 1993-11-05 | Oral pharmaceutical preparation releasable in the lower digestive tract |
DE69332082T DE69332082T2 (de) | 1992-11-06 | 1993-11-05 | Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP32247892 | 1992-11-06 | ||
JP4/322478 | 1992-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994010983A1 true WO1994010983A1 (en) | 1994-05-26 |
Family
ID=18144084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001608 WO1994010983A1 (en) | 1992-11-06 | 1993-11-05 | Peroral pharmaceutical preparation releasable in lower digestive tract |
Country Status (9)
Country | Link |
---|---|
US (1) | US5654004A (ja) |
EP (1) | EP0667148B1 (ja) |
KR (1) | KR0157280B1 (ja) |
AU (1) | AU5376894A (ja) |
CA (1) | CA2148465C (ja) |
DE (1) | DE69332082T2 (ja) |
DK (1) | DK0667148T3 (ja) |
ES (1) | ES2176209T3 (ja) |
WO (1) | WO1994010983A1 (ja) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011032A1 (en) * | 1993-10-19 | 1995-04-27 | The Procter & Gamble Company | Senna dosage form |
WO1998005310A1 (fr) * | 1996-08-02 | 1998-02-12 | Hisamitsu Pharmaceutical Co., Inc. | Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale |
JPH10152431A (ja) * | 1996-08-02 | 1998-06-09 | Hisamitsu Pharmaceut Co Inc | 経口製剤用カプセルと経口カプセル製剤 |
WO1999059639A1 (fr) * | 1998-05-19 | 1999-11-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations solides pour administration orale de medicaments relatifs a des genes |
WO2000016784A1 (fr) * | 1998-09-21 | 2000-03-30 | Amato Pharmaceutical Products, Ltd. | Systeme d'administration orale de medicament permettant d'ameliorer la biodisponibilite de la glycyrrhetine activee |
WO2000043041A1 (fr) * | 1999-01-22 | 2000-07-27 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicamenteuses presentant une meilleure absorption orale |
US6309666B1 (en) | 1995-07-20 | 2001-10-30 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
KR100336975B1 (ko) * | 1998-08-11 | 2002-08-22 | 한국화학연구원 | 약물방출제어용패취 |
JP2002537321A (ja) * | 1999-02-22 | 2002-11-05 | エラン コーポレイション ピーエルスィー | 促進剤を含む固体経口剤形 |
JP2003201256A (ja) * | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
US6620834B1 (en) | 1999-07-02 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
WO2004087109A1 (ja) * | 2003-03-27 | 2004-10-14 | Hisamitsu Pharmaceutical Co., Inc. | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
JP2005289825A (ja) * | 2004-03-31 | 2005-10-20 | Meruku Hoei Kk | シクロスポリン製剤 |
JP2007524575A (ja) * | 2003-01-30 | 2007-08-30 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
WO2008117814A1 (ja) * | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
WO2009048073A1 (ja) * | 2007-10-09 | 2009-04-16 | Takeda Pharmaceutical Company Limited | 顆粒の被覆方法 |
US8053429B2 (en) | 1999-02-22 | 2011-11-08 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8802114B2 (en) | 2011-01-07 | 2014-08-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
US8883201B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8999383B2 (en) | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
KR100522248B1 (ko) * | 1997-05-29 | 2006-02-01 | 동아제약주식회사 | 이중제어방출막구조의경구서방성제제및그제조방법 |
DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
JPH11246439A (ja) * | 1998-03-02 | 1999-09-14 | Hisamitsu Pharmaceut Co Inc | 経粘膜用吸収促進剤 |
US7101575B2 (en) | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
EP0972563A1 (en) * | 1998-07-15 | 2000-01-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates |
ATE524166T1 (de) * | 1998-03-19 | 2011-09-15 | Max Planck Gesellschaft | Kapseln enthaltend lipide in der hülle |
EP1064088B1 (en) | 1998-03-19 | 2002-12-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates |
US6197347B1 (en) | 1998-06-29 | 2001-03-06 | Andrx Pharmaceuticals, Inc. | Oral dosage for the controlled release of analgesic |
FR2781666B1 (fr) * | 1998-07-30 | 2000-09-08 | Oreal | Composition cosmetique solide et ses utilisations |
JP2000247911A (ja) * | 1999-02-26 | 2000-09-12 | Hisamitsu Pharmaceut Co Inc | 大腸用吸収促進剤 |
EP1194128A2 (en) | 1999-06-23 | 2002-04-10 | Sedum Laboratories | Ionically formulated biomolecule microcarriers |
DE19943420A1 (de) * | 1999-09-08 | 2001-03-15 | Beiersdorf Ag | Mascara und Augenbrauenstifte mit einem Gehalt an fluormodifizierten Kammpolymeren |
US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
PT1276470E (pt) | 2000-04-20 | 2007-08-13 | Novartis Ag | Composição de revestimento para dissimular o sabor |
US6551617B1 (en) | 2000-04-20 | 2003-04-22 | Bristol-Myers Squibb Company | Taste masking coating composition |
KR100411195B1 (ko) * | 2000-09-26 | 2003-12-18 | 한국화학연구원 | 케토롤락 트로메타민이 함유된 서방형 펠렛 |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
DK1456380T3 (da) * | 2001-11-02 | 2012-07-30 | Giuliani Int Ltd | SMAD7-inhibitorer til behandling af CNS-sygdomme |
US7007417B2 (en) * | 2002-01-18 | 2006-03-07 | M.H. Segan Limited Partnership | Audio-visual display device for pictorial artwork |
TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
US7348399B2 (en) | 2003-08-29 | 2008-03-25 | Louisiana Tech University Foundation, Inc. | Nanofabricated polypeptide multilayer films, coatings, and microcapsules |
US7550557B2 (en) | 2003-08-29 | 2009-06-23 | Louisiana Tech University Foundation, Inc. | Multilayer films, coatings, and microcapsules comprising polypeptides |
US7544770B2 (en) | 2003-08-29 | 2009-06-09 | Louisiana Tech Foundation, Inc. | Multilayer films, coatings, and microcapsules comprising polypeptides |
US7670624B2 (en) * | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
DE102004013637A1 (de) | 2004-03-19 | 2005-10-13 | Capsulution Nanoscience Ag | Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln |
DE102004035936A1 (de) * | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
CN100486568C (zh) * | 2004-08-26 | 2009-05-13 | 复旦大学 | 洛索洛芬钠缓释制剂 |
CN101259140B (zh) * | 2007-03-08 | 2012-08-22 | 重庆北碚现代应用药物研究所 | 一种治疗胃炎、胃溃疡及十二指肠溃疡的复方药物及其制备方法 |
DE102008003615A1 (de) | 2008-01-09 | 2009-07-16 | Magforce Nanotechnologies Ag | Magnetische Transducer |
EP2172193A1 (en) * | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Improved nanoparticulate compositions of poorly soluble compounds |
EP2742515B1 (en) | 2011-08-10 | 2016-04-13 | MagForce AG | Medical device comprising agglomerated magnetic alkoxysilane-coated nanoparticles |
NO2659881T3 (ja) * | 2012-04-30 | 2018-04-28 | ||
JP6294457B2 (ja) | 2013-03-15 | 2018-03-14 | ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc | 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58501174A (ja) * | 1981-07-31 | 1983-07-21 | ティロッツ・ファルマ・アクチエンゲゼルシャフト | 経口投与可能な薬剤組成物 |
JPH04225922A (ja) * | 1990-04-23 | 1992-08-14 | Teikoku Seiyaku Co Ltd | 大腸崩壊性ポリペプチド系経口製剤 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2246037B2 (de) * | 1972-09-20 | 1975-02-27 | Taeschner & Co, 8831 Kipfenberg | Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform |
FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
FR2576213B1 (fr) * | 1985-01-21 | 1989-02-24 | Cortial | Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee |
US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
US5296236A (en) * | 1988-09-16 | 1994-03-22 | Recordati S.A., Chemical And Pharmaceutical Company | Controlled release therapeutic system for a liquid pharmaceutical formulations |
US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
-
1993
- 1993-11-05 US US08/432,202 patent/US5654004A/en not_active Expired - Fee Related
- 1993-11-05 WO PCT/JP1993/001608 patent/WO1994010983A1/ja active IP Right Grant
- 1993-11-05 DK DK93924185T patent/DK0667148T3/da active
- 1993-11-05 DE DE69332082T patent/DE69332082T2/de not_active Expired - Fee Related
- 1993-11-05 ES ES93924185T patent/ES2176209T3/es not_active Expired - Lifetime
- 1993-11-05 AU AU53768/94A patent/AU5376894A/en not_active Abandoned
- 1993-11-05 EP EP93924185A patent/EP0667148B1/en not_active Expired - Lifetime
- 1993-11-05 KR KR1019950701773A patent/KR0157280B1/ko not_active IP Right Cessation
- 1993-11-05 CA CA002148465A patent/CA2148465C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58501174A (ja) * | 1981-07-31 | 1983-07-21 | ティロッツ・ファルマ・アクチエンゲゼルシャフト | 経口投与可能な薬剤組成物 |
JPH04225922A (ja) * | 1990-04-23 | 1992-08-14 | Teikoku Seiyaku Co Ltd | 大腸崩壊性ポリペプチド系経口製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0667148A4 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5514663A (en) * | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
WO1995011032A1 (en) * | 1993-10-19 | 1995-04-27 | The Procter & Gamble Company | Senna dosage form |
US6309666B1 (en) | 1995-07-20 | 2001-10-30 | Tanabe Seiyaku Co., Ltd. | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
WO1998005310A1 (fr) * | 1996-08-02 | 1998-02-12 | Hisamitsu Pharmaceutical Co., Inc. | Gelules destinees a des preparations orales et preparations de gelules destinees a une administration orale |
JPH10152431A (ja) * | 1996-08-02 | 1998-06-09 | Hisamitsu Pharmaceut Co Inc | 経口製剤用カプセルと経口カプセル製剤 |
CN1088584C (zh) * | 1996-08-02 | 2002-08-07 | 久光制药株式会社 | 口服制剂用胶囊及口服胶囊制剂 |
US6794367B1 (en) | 1998-05-19 | 2004-09-21 | Hisamitsu Pharmaceutical, Inc. | Solid preparations for oral administration of drugs relating to genes |
WO1999059639A1 (fr) * | 1998-05-19 | 1999-11-25 | Hisamitsu Pharmaceutical Co., Inc. | Preparations solides pour administration orale de medicaments relatifs a des genes |
AU748966B2 (en) * | 1998-05-19 | 2002-06-13 | Hisamitsu Pharmaceutical Co., Inc. | Solid preparations for oral administration of drugs relating to genes |
KR100336975B1 (ko) * | 1998-08-11 | 2002-08-22 | 한국화학연구원 | 약물방출제어용패취 |
WO2000016784A1 (fr) * | 1998-09-21 | 2000-03-30 | Amato Pharmaceutical Products, Ltd. | Systeme d'administration orale de medicament permettant d'ameliorer la biodisponibilite de la glycyrrhetine activee |
WO2000043041A1 (fr) * | 1999-01-22 | 2000-07-27 | Yamanouchi Pharmaceutical Co., Ltd. | Compositions medicamenteuses presentant une meilleure absorption orale |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
JP2002537321A (ja) * | 1999-02-22 | 2002-11-05 | エラン コーポレイション ピーエルスィー | 促進剤を含む固体経口剤形 |
US8828431B2 (en) | 1999-02-22 | 2014-09-09 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8323690B2 (en) | 1999-02-22 | 2012-12-04 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8323689B2 (en) | 1999-02-22 | 2012-12-04 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
JP2012067115A (ja) * | 1999-02-22 | 2012-04-05 | Merrion Research Iii Ltd | 促進剤を含む固体経口剤形 |
US8053429B2 (en) | 1999-02-22 | 2011-11-08 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US6620834B1 (en) | 1999-07-02 | 2003-09-16 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
JP2003201256A (ja) * | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
JP2007524575A (ja) * | 2003-01-30 | 2007-08-30 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
JP4699350B2 (ja) * | 2003-01-30 | 2011-06-08 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
WO2004087109A1 (ja) * | 2003-03-27 | 2004-10-14 | Hisamitsu Pharmaceutical Co., Inc. | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
JP2005289825A (ja) * | 2004-03-31 | 2005-10-20 | Meruku Hoei Kk | シクロスポリン製剤 |
JP4521554B2 (ja) * | 2004-03-31 | 2010-08-11 | マイラン製薬株式会社 | シクロスポリン製剤 |
US8883201B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8883203B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
WO2008117814A1 (ja) * | 2007-03-26 | 2008-10-02 | Teikoku Seiyaku Co., Ltd. | 大腸送達用経口製剤 |
JPWO2008117814A1 (ja) * | 2007-03-26 | 2010-07-15 | 帝國製薬株式会社 | 大腸送達用経口製剤 |
WO2009048073A1 (ja) * | 2007-10-09 | 2009-04-16 | Takeda Pharmaceutical Company Limited | 顆粒の被覆方法 |
US8999383B2 (en) | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US8802114B2 (en) | 2011-01-07 | 2014-08-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
Also Published As
Publication number | Publication date |
---|---|
AU5376894A (en) | 1994-06-08 |
EP0667148A4 (en) | 1997-02-26 |
KR950703938A (ko) | 1995-11-17 |
ES2176209T3 (es) | 2002-12-01 |
CA2148465C (en) | 1999-11-02 |
EP0667148A1 (en) | 1995-08-16 |
US5654004A (en) | 1997-08-05 |
KR0157280B1 (ko) | 1998-11-16 |
DE69332082T2 (de) | 2003-02-06 |
DK0667148T3 (da) | 2002-07-22 |
DE69332082D1 (de) | 2002-08-08 |
CA2148465A1 (en) | 1994-05-26 |
EP0667148B1 (en) | 2002-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994010983A1 (en) | Peroral pharmaceutical preparation releasable in lower digestive tract | |
US5171580A (en) | Orally-pharmaceutical preparations with colon selective delivery | |
CA2268175C (en) | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery | |
AU736951B2 (en) | Biphasic controlled release delivery system for high solubility pharmaceuticals and method | |
US8709996B2 (en) | Pharmaceutical treatment process using chitosan or derivative thereof | |
US6479075B1 (en) | Pharmaceutical formulations for acid labile substances | |
JP2009539862A (ja) | 強化剤を含む固体経口投与剤形 | |
JPH11505253A (ja) | 結腸デリバリー用の医薬投与形態 | |
JP3134187B2 (ja) | 放出制御組成物 | |
JPH0222222A (ja) | 有効物質を制御して放出する経口投与用の薬学的製剤、及びその製造方法 | |
EP0616802A1 (en) | Oral preparation for release in lower digestive tracts | |
JP2821952B2 (ja) | 下部消化管放出性の経口医薬製剤 | |
US20110250238A1 (en) | System for the colon delivery of drugs subject to enzyme degradation and/or poorly absorbed in the gastrointestinal tract | |
JP5013871B2 (ja) | 経口徐放性医薬組成物 | |
WO1990013286A1 (fr) | Preparation orale pouvant etre liberee dans une region appropriee de l'intestin | |
JP2003201256A (ja) | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 | |
JP3122478B2 (ja) | 下部消化管放出型経口製剤 | |
EP3796908B1 (en) | Controlled release propiverine formulations | |
JP3282832B2 (ja) | 持続性錠剤 | |
WO2005065685A1 (en) | Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer | |
WO2001064253A1 (fr) | Compositions medicinales renfermant un agent modificateur de la glycoproteine p pour administration au gros intestin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993924185 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2148465 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08432202 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993924185 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993924185 Country of ref document: EP |